GHO Capital raises over €2.5B Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 27 October, 2025

Start your year where biopharma sets its agenda. Join Endpoints News and industry leaders in San Francisco as we unpack the forces shaping dealmaking, China's emerging role and regulatory shifts. Save $200 with Early Bird rates — reserve your spot today.

presented by Gene Ther­a­py for the Mass­es: Ex­pand­ing the Treat­ment Par­a­digm with HCAd

spotlight Real progress, 'stupid' money and moonshots: A big, long list of takeaways from our second ‘AI Day’

news GSK to license Empirico’s COPD candidate for $85M upfront Startup launches with $80M and a plan to teach the immune system to make better Tregs GHO Capital gets $2.9B for fourth healthcare PE fund Novartis could sell more drugs through direct-to-patient service

Nov 12 2:30pm ET From JP Morgan to the next wave: What's driving biotech in 2026 sponsored by Precision AQ Nov 13 11:00am ET Driving down the cost: Optimising CGT with the right CDMO partner sponsored by OXB

Biopharma is entering a new era of AI-driven discovery and precision medicine — but growth is challenged by regulatory shifts and global uncertainty. Join us in London to hear from the leaders shaping what’s next.

endpoints pharma Intellia pauses two CRISPR trials after liver toxicity hospitalizes patient FDA names Mary Thanh Hai as permanent director of Office of New Drugs Organon CEO exits after internal probe over 'channel stuffing' to boost sales Cigna says it will move to end drug rebates beginning in 2027

in case you missed it 1. Novartis CEO says $12B Avidity deal could have been 'twice as big' •  Novartis to buy RNA drugmaker Avidity Biosciences for $12B 2. BridgeBio shifts filing plans for rare disease drug after Phase 3 success 3. Zenas’ multiple sclerosis drug slows new brain lesions in mid-stage trial 4. Exclusive: Scottish microRNA startup claims signs of success in Phase 2 tendinopathy study 5. News Briefing FDA approves Syndax’s menin inhibitor with black-box warning; GSK’s ADC deal 6. Novo ended Akero deal talks before returning for $4.7B MASH acquisition